Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05980806 · ClinicalTrials.gov registry record · Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
A Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia, sponsored by Karyopharm Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT05980806: Recruiting Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia, sponsored by Karyopharm Therapeutics.
NCT05980806 is a Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 58 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05980806, a Phase 2 study of Myelofibrosis and Moderate Thrombocytopenia, is actively recruiting participants, sponsored by Karyopharm Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Primary Outcome
Measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan by Investigator assessment.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Momelotinib
- DRUG Pacritinib
- DRUG Selinexor 60 mg
- DRUG Selinexor 40 mg
Study Locations (20)
Other
- UZ Gent - Ghent
- UZ Leuven - Campus Gasthuisberg - Leuven
- University Multiprofile Hospital for Active Treatment Sveti George - Base 1 - Plovdiv
- University Hospital Sv.Ivan Rilski - Sofia - Sofia
- University Multiprofile Hospital for Active Treatment Aleksandrovska - Sofia
- Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia - Sofia
- University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology - Stara Zagora
- Fakultní nemocnice Olomouc - Olomouc
California
- City of Hope - Duarte Main Site - Duarte
Maryland
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology - Columbia
New York
- Weill Cornell Medicine NewYork-Presbyterian - New York
North Carolina
- Duke University - Durham
Ohio
- Cleveland Clinic - Cleveland
Texas
- MD Anderson - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What NCT05980806 shows while recruiting
NCT05980806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 5 interventions - of which Ruxolitinib is the first listed.
NCT05980806 names 20 study sites across 13 states, led by Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05980806 about?
NCT05980806 is a clinical study titled "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia". The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed...
What is the current status of trial NCT05980806?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-04-22. Estimated completion is 2028-10.
What conditions does trial NCT05980806 study?
This clinical trial studies the following conditions: Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia.
What interventions are being tested in trial NCT05980806?
The interventions under investigation include: Ruxolitinib (DRUG), Momelotinib (DRUG), Pacritinib (DRUG), Selinexor 60 mg (DRUG), Selinexor 40 mg (DRUG).
Who is sponsoring clinical trial NCT05980806?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05980806 being conducted?
This trial has 20 study locations across California, Maryland, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05980806's enrollment target sits among peer trials
58 30th of 61 higher than 32 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI